{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:23:10Z","timestamp":1785360190119,"version":"3.55.0"},"reference-count":196,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease deriving from the hair follicles. The formation of inflammatory nodules, abscesses, fistulas, and sinus tracts is characterized by a large inflow of key pro-inflammatory mediators, such as IFN-\u03b3, TNF-\u03b1, IL-1, IL-17, and IL-12\/23. Adalimumab is currently the only Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved biologic therapy for moderate to severe HS in adults and adolescents. However, the long-term effectiveness of this TNF-\u03b1 inhibitor in HS patients has shown to be highly variable. This review aims to review the evidence for emerging therapies that target the main pro-inflammatory cytokines in HS pathogenesis. A review of the literature was conducted, using the PubMed and Google Scholar repositories, as well as Clinicaltrials.gov. Presently, the most promising biologics in phase III trials are anti-IL-17 antibodies, secukinumab, and bimekizumab. Furthermore, an anti-IL-1 biologic, bermekimab, is currently in phase II trials, and shows encouraging results. Overall, the clinical efficacies of all new targeted therapies published up to this point are limited. More studies need to be performed to clarify the precise molecular pathology, and assess the efficacy of biological therapies for HS.<\/jats:p>","DOI":"10.3390\/ijms23073753","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:44:52Z","timestamp":1648590292000},"page":"3753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["New and Emerging Targeted Therapies for Hidradenitis Suppurativa"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5964-8982","authenticated-orcid":false,"given":"Adela","family":"Markota \u010cagalj","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, University Hospital Centre Split, Spin\u010di\u0107eva 1, 21000 Split, Croatia"},{"name":"School of Medicine, University of Split, \u0160oltanska 2, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"Department of Dermatology and Venereology, European Reference Network (ERN), Skin Reference Centre, University Hospital Centre Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Bukvi\u0107 Mokos","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"Department of Dermatology and Venereology, European Reference Network (ERN), Skin Reference Centre, University Hospital Centre Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis Suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ad.2015.06.004","article-title":"An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity","volume":"106","author":"Martorell","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of Hidradenitis Suppurativa in the United States: A Sex- and Age-Adjusted Population Analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis Suppurativa: From Pathogenesis to Diagnosis and Treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_5","first-page":"2017959","article-title":"Hidradenitis Suppurativa in Kuala Lumpur, Malaysia: A 7-Year Retrospective Review","volume":"2018","year":"2018","journal-title":"Dermatol. Res. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/bjs.6569","article-title":"Hidradenitis Suppurativa","volume":"96","author":"Buimer","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/archdermatol.2011.1950","article-title":"A Systematic Review of Treatments for Hidradenitis Suppurativa","volume":"148","author":"Rambhatla","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New Insights into the Diagnosis of Hidradenitis Suppurativa: Clinical Presentations and Phenotypes","volume":"73","author":"Jemec","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients with Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2 Adalimumab Study","volume":"30","author":"Kimball","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and Validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a Novel Dynamic Scoring System to Assess HS Severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","unstructured":"Shi, V.Y., Hsiao, J.L., Lowes, M., and Hamzavi, I. (2021). A Comprehensive Guide to Hidradenitis Suppurativa\u2014EBook, Elsevier Health Sciences."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/BTT.S199862","article-title":"Systematic Review of Immunomodulatory Therapies for Hidradenitis Suppurativa","volume":"13","author":"Lim","year":"2019","journal-title":"Biol. Targets Ther."},{"key":"ref_14","first-page":"e32","article-title":"Mutations in the Gamma-Secretase Genes NCSTN, PSENEN and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa)","volume":"166","author":"Pink","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1203475419852049","article-title":"Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes","volume":"23","author":"Jfri","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1159\/000512455","article-title":"\u03b3-Secretase Genetics of Hidradenitis Suppurativa: A Systematic Literature Review","volume":"237","author":"Wang","year":"2021","journal-title":"Dermatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/exd.12098","article-title":"Impaired Notch-MKP-1 Signalling in Hidradenitis Suppurativa: An Approach to Pathogenesis by Evidence from Translational Biology","volume":"22","author":"Melnik","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_18","unstructured":"Rice, A.S., and Cook, C. (2022). Dowling Degos Disease. StatPearls, StatPearls Publishing."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1164\/rccm.200705-795OC","article-title":"Down-Regulation of the Notch Pathway in Human Airway Epithelium in Association with Smoking and Chronic Obstructive Pulmonary Disease","volume":"179","author":"Tilley","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tem.2015.02.006","article-title":"Notch Signaling as a Novel Regulator of Metabolism","volume":"26","author":"Bi","year":"2015","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical Practice. Hidradenitis Suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature10759","article-title":"Inflammasomes in Health and Disease","volume":"481","author":"Strowig","year":"2012","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ni.2257","article-title":"Inflammasomes: Far beyond Inflammation","volume":"13","author":"Elinav","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3810\/pgm.2010.09.2209","article-title":"Inflammasome Mediated Autoinflammatory Disorders","volume":"122","author":"Wilson","year":"2010","journal-title":"Postgrad. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jid.2017.04.024","article-title":"Hidradenitis Suppurativa Is Associated with Familial Mediterranean Fever\u2014A Population-Based Study","volume":"137","author":"Hodak","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","article-title":"Pyogenic Arthritis, Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa (PAPASH): A New Autoinflammatory Syndrome Associated with a Novel Mutation of the PSTPIP1 Gene","volume":"149","author":"Marzano","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bjd.14383","article-title":"PSTPIP1 Gene Mutation in a Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis (PASH) Syndrome","volume":"175","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.det.2015.08.011","article-title":"The Role of Mechanical Stress in Hidradenitis Suppurativa","volume":"34","author":"Boer","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clindermatol.2017.09.007","article-title":"Hidradenitis Suppurativa and the Metabolic Syndrome","volume":"36","author":"Ergun","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_30","first-page":"8","article-title":"Hidradenitis Suppurativa and Associated Diseases","volume":"153","author":"Pescitelli","year":"2018","journal-title":"G. Ital. Dermatol. E Venereol. Organo Uff. Soc. Ital. Dermatol. E Sifilogr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2017.08.042","article-title":"Hidradenitis Suppurativa and Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"78","author":"Bui","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/ijd.14465","article-title":"Diet in Hidradenitis Suppurativa: A Review of Published and Lay Literature","volume":"58","author":"Youssef","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_33","first-page":"9","article-title":"Understanding the Relationship Between Smoking and Hidradenitis Suppurativa","volume":"28","year":"2020","journal-title":"Acta Dermatovenerol. Croat. ADC"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Langan, E.A., Recke, A., Bokor-Billmann, T., Billmann, F., Kahle, B.K., and Zillikens, D. (2020). The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa\u2014Light at the End of the Microbiological Tunnel. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041205"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/cjp.cjp_67_21","article-title":"Hidradenitis Suppurativa: Disease Pathophysiology and Sex Hormones","volume":"64","author":"Chu","year":"2021","journal-title":"Chin. J. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","article-title":"Comorbidities of Hidradenitis Suppurativa: A Review of the Literature","volume":"5","author":"Cartron","year":"2019","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/09546634.2019.1613483","article-title":"Hidradenitis Suppurativa and Risk of Suicide\u2014Systematic Review and Meta-Analysis","volume":"31","author":"Phan","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"204062232110559","DOI":"10.1177\/20406223211055920","article-title":"New Perspectives on the Treatment of Hidradenitis Suppurativa","volume":"12","author":"Vilarrasa","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2018.00639","article-title":"Complement Activation in Inflammatory Skin Diseases","volume":"9","author":"Giang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Del Duca, E., Morelli, P., Bennardo, L., Di Raimondo, C., and Nistic\u00f2, S.P. (2020). Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228436"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of Effector CD4 T Cell Populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08820139.2016.1230867","article-title":"Interferon-Gamma (IFN-\u03b3) Is Elevated in Wound Exudate from Hidradenitis Suppurativa","volume":"46","author":"Banerjee","year":"2017","journal-title":"Immunol. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis Suppurativa: Epidemiology, Clinical Presentation, and Pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/09546634.2017.1395806","article-title":"Targeted Treatments for Hidradenitis Suppurativa: A Review of the Current Literature and Ongoing Clinical Trials","volume":"29","author":"Maarouf","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/jdv.15160","article-title":"Anti-TNF-\u03b1 Therapy Modulates MTORC1 Signalling in Hidradenitis Suppurativa","volume":"33","author":"Balato","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jaci.2018.01.003","article-title":"Human TH17 Cell Development Requires Processing of Dendritic Cell-Derived CXCL8 by Neutrophil Elastase","volume":"141","author":"Souwer","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased Interleukin (IL)-17 Serum Levels in Patients with Hidradenitis Suppurativa: Implications for Treatment with Anti-IL-17 Agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in Inflammatory Skin Diseases Psoriasis and Hidradenitis Suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_51","first-page":"100001","article-title":"Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions","volume":"1","author":"Jiang","year":"2021","journal-title":"JID Innov. Skin Sci. Mol. Popul. Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.it.2018.10.003","article-title":"Bystander T Cells: A Balancing Act of Friends and Foes","volume":"39","author":"Whiteside","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 Guideline for the Treatment of Hidradenitis Suppurativa\/Acne Inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-Based Approach to the Treatment of Hidradenitis Suppurativa\/Acne Inversa, Based on the European Guidelines for Hidradenitis Suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical Clindamycin versus Systemic Tetracycline in the Treatment of Hidradenitis Suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","unstructured":"Kirby, J.S., and Milton, S. (2022, February 06). Exploratory Trial of Ruxolitinib 1.5% Cream for the Treatment of Early Stage Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04414514."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, Evaluation, and the Use of Complementary and Procedural Management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","first-page":"247","article-title":"Smjernice za Dijagnostiku i Lije\u010denje Gnojnog Hidradnitisa (Hidradenitis Suppurativa) Lije\u010d","volume":"139","author":"Brajac","year":"2017","journal-title":"Vjesn."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and Other Tetracycline-Derivative Staining of the Teeth and Oral Cavity","volume":"43","author":"Rogers","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_60","first-page":"49","article-title":"Efficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis Suppurativa","volume":"222","author":"Coignard","year":"2011","journal-title":"Dermatol. Basel Switz."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.mayocp.2015.08.020","article-title":"Hidradenitis Suppurativa: A Guide for the Practicing Physician","volume":"90","author":"Woodruff","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40257-015-0118-8","article-title":"The Medical and Laser Management of Hidradenitis Suppurativa","volume":"16","author":"Hughes","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and Factors Associated with Hidradenitis Suppurativa: Results from Two Case-Control Studies","volume":"59","author":"Revuz","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","unstructured":"Ellis, C.R., and Azmat, C.E. (2022). Adalimumab. StatPearls, StatPearls Publishing."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40257-016-0220-6","article-title":"Adalimumab: A Review in Hidradenitis Suppurativa","volume":"17","author":"Kim","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","article-title":"Hidradenitis Suppurativa: Current and Emerging Treatments","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14712598.2020.1732918","article-title":"Biologic Therapies for the Treatment of Hidradenitis Suppurativa","volume":"20","author":"Morss","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-Term Adalimumab Efficacy in Patients with Moderate-to-Severe Hidradenitis Suppurativa\/Acne Inversa: 3-Year Results of a Phase 3 Open-Label Extension Study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e14643","DOI":"10.1111\/dth.14643","article-title":"Real Life Data on the Biopsychosocial Effects of Adalimumab in the Management of Hidradenitis Suppurativa: A Multicenter Cross Sectional Analysis and Consideration of a Multisystem Monitoring Approach to Follow Up","volume":"34","author":"Muralidharan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic Drug Monitoring with Biologic Agents in Immune Mediated Inflammatory Diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00575-3","article-title":"Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series","volume":"22","author":"Abdalla","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u201cwindow of Opportunity\u201d in Hidradenitis Suppurativa Treated with Adalimumab: A Retrospective, Real-Life Multicentre Cohort Study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_74","first-page":"241","article-title":"Current Systemic Treatment Strategies for Hidradenitis Suppurativa","volume":"5","author":"Ponikowska","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the Treatment of Hidradenitis Suppurativa\/Acne Inversa","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational Case Series on Adalimumab-Induced Paradoxical Hidradenitis Suppurativa","volume":"27","author":"Delobeau","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","article-title":"Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis","volume":"19","author":"Ryan","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e14387","DOI":"10.1111\/dth.14387","article-title":"Clinical Experience with Adalimumab Biosimilar Imraldi in Hidradenitis Suppurativa","volume":"33","author":"Ricceri","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_79","unstructured":"Fatima, R., Bittar, K., and Aziz, M. (2022). Infliximab. StatPearls, StatPearls Publishing."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab Therapy for Patients with Moderate to Severe Hidradenitis Suppurativa: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial","volume":"62","author":"Grant","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-Term Efficacy of a Single Course of Infliximab in Hidradenitis Suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the Optimal Dose of Infliximab for Treatment of Hidradenitis Suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-Dose, High-Frequency Infliximab: A Novel Treatment Paradigm for Hidradenitis Suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-Term Course of Demyelinating Neuropathies Occurring during Tumor Necrosis Factor-Alpha-Blocker Therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/JCM.06161-11","article-title":"Gemella Morbillorum Bacteremia after Anti-Tumor Necrosis Factor Alpha as Acne Inversa Therapy","volume":"50","author":"Vossen","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5070\/D3203021764","article-title":"A Case of a Patient with Stage III Familial Hidradenitis Suppurativa Treated with 3 Courses of Infliximab and Died of Metastatic Squamous Cell Carcinoma","volume":"20","author":"Scheinfeld","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.19863","article-title":"Adalimumab and Infliximab Survival in Patients with Hidradenitis Suppurativa: A Daily Practice Cohort Study","volume":"185","author":"Prens","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2021.0220","article-title":"Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-Abda Therapy for Patients with Hidradenitis Suppurativa","volume":"157","author":"Westerkam","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_89","unstructured":"Pan, A., and Gerriets, V. (2022). Etanercept. StatPearls, StatPearls Publishing."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of Hidradenitis Suppurativa with Etanercept Injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_91","unstructured":"Padda, I.S., Bhatt, R., and Parmar, M. (2022). Golimumab. StatPearls, StatPearls Publishing."},{"key":"ref_92","first-page":"97","article-title":"Failure of Anti-Interleukin-1 Therapy in Severe Hidradenitis Suppurativa: A Case Report","volume":"226","author":"Prens","year":"2013","journal-title":"Dermatol. Basel Switz."},{"key":"ref_93","first-page":"1511","article-title":"Concomitant Hidradenitis Suppurativa and Pyostomatitis Vegetans in Silent Ulcerative Colitis Successfully Treated with Golimumab","volume":"48","author":"Tursi","year":"2016","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab Pegol","volume":"2","author":"Goel","year":"2010","journal-title":"mAbs"},{"key":"ref_95","first-page":"e140","article-title":"Treatment of Hidradenitis Suppurativa with Certolizumab Pegol during Pregnancy","volume":"60","author":"Alhusayen","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e14494","DOI":"10.1111\/dth.14494","article-title":"Certolizumab Pegol for Hidradenitis Suppurativa: Case Report and Literature Review","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000511284","article-title":"Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report","volume":"7","author":"Esme","year":"2021","journal-title":"Skin Appendage Disord."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-Label Use of TNF-Alpha Inhibitors in a Dermatological University Department: Retrospective Evaluation of 118 Patients","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_99","unstructured":"Aboobacker, S., Kurn, H., and Al Aboud, A.M. (2022). Secukinumab. StatPearls, StatPearls Publishing."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-Label, Investigator-Initiated, Single-Site Exploratory Trial Evaluating Secukinumab, an Anti-Interleukin-17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the Treatment of Moderate to Severe Hidradenitis Suppurativa: Results of an Open-Label Trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_102","first-page":"e750","article-title":"Effectiveness of Secukinumab in Hidradenitis Suppurativa: An Open Study (20 Cases)","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical Gastrointestinal Effects of Interleukin-17 Blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.jid.2016.04.003","article-title":"Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Cross-Sectional Study of 3207 Patients","volume":"136","author":"Shalom","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of Secukinumab in the Treatment of Moderate-Severe Hidradenitis Suppurativa: Results from an Italian Multicentric Retrospective Study in a Real-Life Setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","article-title":"Secukinumab and Hidradenitis Suppurativa: Friends or Foes?","volume":"5","author":"Marasca","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_107","unstructured":"Novartis Pharmaceuticals (2022, January 30). A Randomized, Double-Blind, Multi-Center Study Assessing Short (16 Weeks) and Long-Term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients with Moderate to Severe Hidradenitis Suppurativa (SUNSHINE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713619."},{"key":"ref_108","unstructured":"Novartis Pharmaceuticals (2022, January 20). A Randomized, Double-Blind, Multicenter Study Assessing Short (16 Weeks) and Long-Term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients with Moderate to Severe Hidradenitis Suppurativa (SUNRISE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713632."},{"key":"ref_109","unstructured":"Novartis Pharmaceuticals (2022, January 30). A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179175."},{"key":"ref_110","unstructured":"Golbari, N.M., Basehore, B.M., and Zito, P.M. (2022). Brodalumab. StatPearls, StatPearls Publishing."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The Effect of Subcutaneous Brodalumab on Clinical Disease Activity in Hidradenitis Suppurativa: An Open-Label Cohort Study","volume":"83","author":"Frew","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly Administration of Brodalumab in Hidradenitis Suppurativa: An Open-Label Cohort Study","volume":"184","author":"Frew","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_113","unstructured":"Renert-Yuval, Y. (2022, February 13). A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04979520."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-Blind, Placebo-Controlled Randomized Clinical Trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_116","unstructured":"UCB Biopharma SRL (2022, February 10). A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242446."},{"key":"ref_117","unstructured":"UCB Biopharma SRL (2022, February 10). A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242498."},{"key":"ref_118","unstructured":"UCB Biopharma SRL (2022, February 10). A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04901195."},{"key":"ref_119","unstructured":"Preuss, C.V., and Quick, J. (2022). Ixekizumab. StatPearls, StatPearls Publishing."},{"key":"ref_120","first-page":"788","article-title":"Ixekizumab in Hidradenitis Suppurativa in a Psoriatic Patient","volume":"155","author":"Odorici","year":"2020","journal-title":"G. Ital. Dermatol. E Venereol. Organo Uff. Soc. Ital. Dermatol. E Sifilogr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e13756","DOI":"10.1111\/dth.13756","article-title":"Ixekizumab: An Efficacious Treatment for Both Psoriasis and Hidradenitis Suppurativa","volume":"33","author":"Megna","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2020.12.036","article-title":"Severe Hidradenitis Suppurativa with Herpes Simplex Virus 1 Superinfection and Clinical Responsiveness to Ixekizumab","volume":"9","author":"Reardon","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jdv.17071","article-title":"First-in-Human Study Demonstrating the Safety and Clinical Efficacy of Novel Anti-IL-17A Monoclonal Antibody CJM112 in Moderate to Severe Plaque Psoriasis","volume":"35","author":"Kaul","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_124","unstructured":"Novartis Pharmaceuticals (2022, February 13). A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421172."},{"key":"ref_125","unstructured":"Colquhoun, M., and Kemp, A.K. (2022). Ustekinumab. StatPearls, StatPearls Publishing."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in Hidradenitis Suppurativa: Clinical Results and a Search for Potential Biomarkers in Serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_127","first-page":"21","article-title":"Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa","volume":"236","author":"Vilarrasa","year":"2020","journal-title":"Dermatol. Basel Switz."},{"key":"ref_128","first-page":"e14054","article-title":"Effectiveness and Safety of Ustekinumab in Patients with Hidradenitis Suppurativa Using Intravenous Induction","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/09546634.2020.1755008","article-title":"Ustekinumab in the Treatment of Patients with Hidradenitis Suppurativa: Multicenter Case Series and Systematic Review","volume":"33","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_130","first-page":"1","article-title":"Effectiveness of Ustekinumab for Moderate-to-Severe Hidradenitis Suppurativa: A Case Series","volume":"11","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14712598.2018.1445223","article-title":"Guselkumab for the Treatment of Psoriasis","volume":"18","author":"Megna","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ced.14199","article-title":"Successful Use of Guselkumab in the Treatment of Severe Hidradenitis Suppurativa","volume":"45","author":"Kearney","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_133","first-page":"e140","article-title":"Guselkumab in the Treatment of Severe Hidradenitis Suppurativa","volume":"33","author":"Kovacs","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","article-title":"Guselkumab in the Treatment of Hidradenitis Suppurativa: A Retrospective Chart Review","volume":"81","author":"Casseres","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1654067","article-title":"Guselkumab in the Treatment of Concomitant Hidradenitis Suppurativa, Psoriasis, and Crohn\u2019s Disease","volume":"32","author":"Berman","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_136","first-page":"2874","article-title":"Guselkumab for Hidradenitis Suppurativa in a Patient with Concomitant Crohn\u2019s Disease: Report and Systematic Literature Review of Effectiveness and Safety","volume":"8","author":"Holm","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_137","first-page":"e13456","article-title":"The Use of Guselkumab 100\u2009Mg Every 4\u2009Weeks on Patients with Hidradenitis Suppurativa and a Literature Review","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_138","unstructured":"Janssen Research & Development, LLC (2022, February 23). A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03628924."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: An Anti-IL-23 Antibody for the Treatment of Psoriasis","volume":"12","author":"Haugh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Randomised, Double-Blind, Phase 3 KEEPsAKE 1 Trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/bjd.19716","article-title":"Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Risankizumab after Failure of Anti-Tumour Necrosis Factor Alpha","volume":"184","author":"Marques","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e15116","DOI":"10.1111\/dth.15116","article-title":"Risankizumab Effectiveness in a Recalcitrant Case of Hidradenitis Suppurativa after Anti-TNF and Anti-Interleukin-17 Failures","volume":"34","author":"Pensa","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_143","first-page":"e126","article-title":"A Case of Moderate Hidradenitis Suppurativa and Psoriasis Successfully Treated with Risankizumab","volume":"61","author":"Licata","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_144","unstructured":"AbbVie (2022, February 13). A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926169."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2019.1544493","article-title":"Tildrakizumab for the Treatment of Psoriasis","volume":"15","author":"Sinclair","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1111\/ajd.13377","article-title":"Tildrakizumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa","volume":"61","author":"Kok","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1111\/ajd.13559","article-title":"Tildrakizumab as a Potential Long-Term Therapeutic Agent for Severe Hidradenitis Suppurativa: A 15 Months Experience of an Australian Institution","volume":"62","author":"Kok","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/09546634.2020.1755417","article-title":"Off-Label Studies on Anakinra in Dermatology: A Review","volume":"33","author":"Tegtmeyer","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12969-020-00454-5","article-title":"A Case Report of a Novel Compound Heterozygous Mutation in a Brazilian Patient with Deficiency of Interleukin-1 Receptor Antagonist (DIRA)","volume":"18","author":"Grossi","year":"2020","journal-title":"Pediatr. Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An Open-Label Study of Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful Treatment of Severe Hidradenitis Suppurativa with Anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_153","first-page":"772","article-title":"Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa","volume":"15","author":"Russo","year":"2016","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","article-title":"Two Cases of Severe Hidradenitis Suppurativa with Failure of Anakinra Therapy","volume":"172","author":"Menis","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1551651","DOI":"10.1080\/2162402X.2018.1551651","article-title":"Interleukin-1 Receptor Antagonist Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1\u03b1 Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer","volume":"8","author":"Kurzrock","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 Targeting IL-1\u03b1 for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study","volume":"138","author":"Kanni","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ced.14333","article-title":"MABp1 Targeting Interleukin-1\u03b1 in Hidradenitis Suppurativa Ineligible for Adalimumab Treatment: Results of the Open-Label Extension Period","volume":"46","author":"Kanni","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_159","unstructured":"Janssen Research & Development, LLC (2022, February 14). A Phase 2a\/2b, Multicenter, Randomized, Placebo and Active Comparator-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04988308."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"mAbs"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma Gangrenosum and Concomitant Hidradenitis Suppurativa--Rapid Response to Canakinumab (Anti-IL-1\u03b2)","volume":"23","author":"Jaeger","year":"2013","journal-title":"Eur. J. Dermatol. EJD"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4103\/ijdvl.IJDVL_147_16","article-title":"Hidradenitis Suppurativa Unresponsive to Canakinumab Treatment: A Case Report","volume":"83","author":"Tekin","year":"2017","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_164","first-page":"36","article-title":"Non-Response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for Moderate Hidradenitis Suppurativa: Results of a Randomized Controlled Trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-Term Treatment with Apremilast in Hidradenitis Suppurativa: A 2-Year Follow-up of Initial Responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Case Series of 9 Patients","volume":"76","author":"Weber","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical Efficacy of Complement C5a Inhibition by IFX-1 in Hidradenitis Suppurativa: An Open-Label Single-Arm Trial in Patients Not Eligible for Adalimumab","volume":"183","author":"Argyropoulou","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_169","unstructured":"InflaRx GmbH (2022, February 16). A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects with Moderate to Severe Hidradenitis Suppurativa, Clinical Trial Registration NCT03487276, ClinicalTrials.gov., Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03487276."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: First Approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"ref_171","unstructured":"ChemoCentryx (2022, February 16). A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03852472."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"ref_173","unstructured":"Incyte Corporation (2022, February 16). A Phase 2, Dose-Escalation, Placebo-Controlled Study of INCB054707 in Participants with Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/show\/NCT03569371."},{"key":"ref_174","unstructured":"Incyte Corporation (2022, February 16). A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants with Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03607487."},{"key":"ref_175","unstructured":"Incyte Corporation (2022, February 16). A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants with Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04476043."},{"key":"ref_176","unstructured":"AbbVie (2022, February 16). A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04430855."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib Shows Benefit in Conjunction with Other Therapies in Recalcitrant Hidradenitis Suppurativa Patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_178","unstructured":"Kymera Therapeutics, Inc (2022, February 16). A Phase 1 Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients with Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04772885."},{"key":"ref_179","unstructured":"Pfizer (2022, February 16). A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of PF-06650833, PF-06700841,and PF-06826647 in Adults with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04092452."},{"key":"ref_180","unstructured":"Hanif, N., and Anwer, F. (2022). Rituximab. StatPearls, StatPearls Publishing."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/1346-8138.14144","article-title":"Successful Treatment of Hidradenitis Suppurativa with Rituximab for a Patient with Idiopathic Carpotarsal Osteolysis and Chronic Active Antibody-Mediated Rejection","volume":"45","author":"Takahashi","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_182","unstructured":"Novartis Pharmaceuticals (2022, February 16). A Randomized, Subject and Investigator Blinded, Placebo-Controlled and Multi-Center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03827798."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"144336","DOI":"10.1172\/JCI144336","article-title":"IL-36 in Chronic Inflammation and Fibrosis\u2014Bridging the Gap?","volume":"131","author":"Elias","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_184","unstructured":"Boehringer Ingelheim (2022, February 16). Randomized, Double-Blind, Placebo-Controlled, Study of Spesolimab in Patients with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04762277."},{"key":"ref_185","unstructured":"AnaptysBio, Inc (2022, February 16). A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04856930."},{"key":"ref_186","unstructured":"Eli Lilly and Company (2022, February 16). A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults with Moderate-to-Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04493502."},{"key":"ref_187","unstructured":"CSL Behring (2022, February 16). A Multicenter, Open-Label, 2-Regimen, Repeat-Dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects with Hidradenitis Suppurativa and Palmoplantar Pustulosis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03972280."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.19591","article-title":"Antidrug Antibodies to Tumour Necrosis Factor Inhibitors in Hidradenitis Suppurativa: A Systematic Review","volume":"184","author":"Lu","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_189","first-page":"299","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2017.02.015","article-title":"Anti-Therapeutic Antibodies and Their Clinical Impact in Patients Treated with the TNF Antagonist Adalimumab","volume":"96","author":"Cludts","year":"2017","journal-title":"Cytokine"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Lipa, K., Zaj\u0105c, N., Witkowski, G., Ciechanowicz, P., Wiszniewski, K., Szyma\u0144ska, E., and Walecka, I. (2022). Hidradenitis Suppurativa\u2014Biologic Therapy and Other Available Treatment Options. Adv. Dermatol. Allergol. Dermatol. Alergol., 38.","DOI":"10.5114\/ada.2021.112075"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14740338.2021.1924147","article-title":"A Safety Review of Biologic Therapies for the Management of Hidradenitis Suppurativa and Unmet Needs","volume":"20","author":"Holcomb","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/exd.14123","article-title":"Endpoints of Clinical Trials for Hidradenitis Suppurativa: Proceedings of a Round-Table Session","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis Suppurativa (HS): An Unrecognized Paradoxical Effect of Biologic Agents (BA) Used in Chronic Inflammatory Diseases","volume":"74","author":"Faivre","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_195","unstructured":"AbbVie (2022, February 16). A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808975."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review","volume":"158","author":"Hessam","year":"2022","journal-title":"JAMA Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:45:56Z","timestamp":1760136356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":196,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23073753"],"URL":"https:\/\/doi.org\/10.3390\/ijms23073753","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}